Distefar Del Sur
Distefar Del Sur is recorded as a service provider in 14 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 14 of 14 trials · Latest update first
A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma
Sponsor Renaissance Pharma Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who are ≥18 to ≤65 Years
Sponsor Sarepta Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 as monotherapy and in combination in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer
Sponsor Ellipses Pharma Limited
- Start (EU)
- Latest update
- Estimated end
Clinical trial to evaluate the efficacy and safety of Depigoid DUO Grass-Mix/Olea (1000 DPP/mL + 1000 DPP/mL) compared with placebo in patients suffering from allergic rhinoconjunctivitis with or without asthma due to clinically relevant sensitisation to grass and olive pollen.
Sponsor LETI Pharma S.L.U.
- Start (EU)
- Latest update
- Estimated end
- Not reported
An interventional Phase 3, open-label, two-cohort study to investigate the efficacy and safety of fosmanogepix in adult patients with invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds
Sponsor Basilea Pharmaceutica International AG Allschwil
- Start (EU)
- Latest update
- Estimated end
A Study to Evaluate the Efficacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis (ELIXIR)
Sponsor Iperboreal Pharma S.r.l.
- Start (EU)
- Latest update
- Estimated end
An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients previously exposed to three-drug classes
Sponsor Pethema Fundacion
- Start (EU)
- Latest update
- Estimated end
- Not reported
A multicenter, open label, randomized phase II trial to evaluate the efficacy of Talazoparib plus Enzalutamide as first line treatment for patients with Metastatic castration resistant Prostate Cancer after progression to an Androgen Receptor Pathway Inhibitor
Sponsor Fundacion Oncosur
- Start (EU)
- Latest update
- Estimated end
- Not reported
Clinical trial to evaluate the efficacy and safety of Depigoid Grass-Mix at 1000 DPP/mL and Depigoid FORTE Grass-Mix at 3000 DPP/mL compared with placebo in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma due to clinically relevant sensitisation to grass pollen.
Sponsor LETI Pharma S.L.U.
- Start (EU)
- Latest update
- Estimated end
- Not reported
International Phase III, Multi-center, Randomized, Double-blind, Placebo and Active-controlled and Parallel group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female patients with Androgenetic Alopecia.
Sponsor Industrial Farmaceutica Cantabria S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies
Sponsor Ellipses Pharma Limited
- Start (EU)
- Latest update
- Estimated end
Non‐Randomized, Open‐Label, Prospective Phase II Trial to Better Characterize the Status of HRD leading to a Benefit from Olaparib in Combination with Bevacizumab in Patients with Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer After Standard First‐Line Treatment. STROBE
Sponsor Vall D Hebron Institute Of Oncology
- Start (EU)
- Latest update
- Estimated end
- Not reported
Bevacizumab plus encorafenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, the BRAVE trial
Sponsor Vall D Hebron Institute Of Oncology
- Start (EU)
- Latest update
- Estimated end
- Not reported
GEM21menos65. A Phase III trial for NDMM patients who are candidates for ASCT comparing Extended VRD plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D.
Sponsor Fundacion PETHEMA
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Distefar Del Sur?
The 2026-10-09 snapshot links Distefar Del Sur to 14 distinct CTIS trials. Recorded services include Medicinal product management, Symptomatic medication Supplier, Expense Reimbursement Management, Medication Logistics, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Distefar Del Sur?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Allergy, Genetic and Congenital Disorders, Infectious Disease. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Distefar Del Sur conducted?
The linked trials record locations in 13 countries, including Spain, Germany, France, Italy, Portugal. These are trial locations, not confirmed office locations or countries where Distefar Del Sur delivered services.
What can this page tell me about Distefar Del Sur's trial experience?
Browse 14 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Distefar Del Sur. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Distefar Del Sur S.L.